Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004105 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy in Treating Patients With Advanced Cancer
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004105: Completed Phase 1 study, sponsored by NYU Langone Health.
NCT00004105 is a Phase 1 study that has completed, run by NYU Langone Health. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004105, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of vinorelbine, paclitaxel, and estramustine in treating patients who have advanced cancer that has not responded to previous treatment.
Interventions
- DRUG paclitaxel
- DRUG estramustine phosphate sodium
- DRUG vinorelbine ditartrate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-09 |
| Phase | Phase 1 |
What the finished NCT00004105 record still lists
NCT00004105 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which paclitaxel is the first listed.
NCT00004105 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004105 about?
NCT00004105 is a clinical study titled "Combination Chemotherapy in Treating Patients With Advanced Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of vinorelbine, paclitaxel, and estramustine in treating patients wh...
What is the current status of trial NCT00004105?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-09.
What interventions are being tested in trial NCT00004105?
The interventions under investigation include: paclitaxel (DRUG), estramustine phosphate sodium (DRUG), vinorelbine ditartrate (DRUG).
Who is sponsoring clinical trial NCT00004105?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia